G93.F Jiangsu Recbio Technology Co., Ltd.

Healthcare Biotechnology Frankfurt Exchange
0.7367 EUR
Close of Nov 12, 2026
0.3540 0.6750
Market cap
EUR 233M
P/E
-
P/B
3.50x
ROE
-86.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is G93.F undervalued?

Graham number

The Graham number of Jiangsu Recbio Technology Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jiangsu Recbio Technology Co., Ltd. fundamental analysis

No fundamental analysis for Jiangsu Recbio Technology Co., Ltd. yet.

Jiangsu Recbio Technology Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical t…

Full company profile